Rapid Molecular Assay Detects Pneumonia Causative Agents
|
By LabMedica International staff writers Posted on 16 May 2012 |
A rapid real-time polymerase chain reaction assay (qPCR) has been developed for detecting two microrganisms that cause pneumonia directly from respiratory specimens.
The assay provides over five times faster results compared to existing methods while maintaining equivalent detection rates for specimens containing limited target organisms such as Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae.
Scientists the Respiratory Diseases Branch, of the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) developed and evaluated individual singleplex assays for each pathogen and a multiplex assay for simultaneous detection of M. pneumoniae, C. pneumoniae, and human DNA. Nasopharyngeal and/or oropharyngeal clinical specimens were collected by the Centers for Disease Control and Prevention during domestic outbreaks between 2007 and 2009.
Primers and probes previously designed and optimized for specific detection of the ATPase Mp3 for M. pneumoniae, the arginine repressor (argR) of C. pneumoniae, and human nucleic acid (RNase P) were used in the study. For singleplex reactions, the reaction mix contained PerfeCTa qPCR FastMix and for multiplex reactions the PerfeCTa Multiplex qPCR SuperMix was used, and both are products of Quanta Biosciences, (Gaithersburg, MD, USA). Total nucleic acid (TNA) was extracted from universal transport media (UTM) using a Nucleic Acid Isolation Kit I on the MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA).
The scientists found a greater than 90% concordance using the rapid singleplex or multiplex assay. They then assessed the performance of the rapid real-time PCR assay using UTM directly from clinical specimens without nucleic acid extraction. Of the specimens identified as positive by standard real-time PCR, 90% and 59% of UTM samples were positive for M. pneumoniae and C. pneumoniae, respectively, using singleplex assays. These percentages dropped to 69% for M. pneumoniae and 52% for C. pneumoniae when tested with the rapid multiplex assay.
The authors concluded that although some loss of sensitivity was observed when performing rapid real-time PCR without a separate extraction step, this method may still be a valuable tool for identification of M. pneumoniae and C. pneumoniae infections in the primary care setting that would otherwise go unnoticed or misdiagnosed. Point-of-care testing would likely improve patient treatment, reduce inappropriate antibiotic use, and have utility for rapid pathogen detection in situations where prompt results are critical. The study was published on April 25 2012 in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
US Centers for Disease Control and Prevention
Quanta Biosciences
Roche Applied Science
The assay provides over five times faster results compared to existing methods while maintaining equivalent detection rates for specimens containing limited target organisms such as Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae.
Scientists the Respiratory Diseases Branch, of the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) developed and evaluated individual singleplex assays for each pathogen and a multiplex assay for simultaneous detection of M. pneumoniae, C. pneumoniae, and human DNA. Nasopharyngeal and/or oropharyngeal clinical specimens were collected by the Centers for Disease Control and Prevention during domestic outbreaks between 2007 and 2009.
Primers and probes previously designed and optimized for specific detection of the ATPase Mp3 for M. pneumoniae, the arginine repressor (argR) of C. pneumoniae, and human nucleic acid (RNase P) were used in the study. For singleplex reactions, the reaction mix contained PerfeCTa qPCR FastMix and for multiplex reactions the PerfeCTa Multiplex qPCR SuperMix was used, and both are products of Quanta Biosciences, (Gaithersburg, MD, USA). Total nucleic acid (TNA) was extracted from universal transport media (UTM) using a Nucleic Acid Isolation Kit I on the MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA).
The scientists found a greater than 90% concordance using the rapid singleplex or multiplex assay. They then assessed the performance of the rapid real-time PCR assay using UTM directly from clinical specimens without nucleic acid extraction. Of the specimens identified as positive by standard real-time PCR, 90% and 59% of UTM samples were positive for M. pneumoniae and C. pneumoniae, respectively, using singleplex assays. These percentages dropped to 69% for M. pneumoniae and 52% for C. pneumoniae when tested with the rapid multiplex assay.
The authors concluded that although some loss of sensitivity was observed when performing rapid real-time PCR without a separate extraction step, this method may still be a valuable tool for identification of M. pneumoniae and C. pneumoniae infections in the primary care setting that would otherwise go unnoticed or misdiagnosed. Point-of-care testing would likely improve patient treatment, reduce inappropriate antibiotic use, and have utility for rapid pathogen detection in situations where prompt results are critical. The study was published on April 25 2012 in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
US Centers for Disease Control and Prevention
Quanta Biosciences
Roche Applied Science
Latest Microbiology News
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
Channels
Clinical Chemistry
view channel
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
Lung cancer care increasingly relies on biomarker-guided patient stratification, but tissue biopsy can be impractical and treatment selection remains difficult for many patients. Blood-based assays that... Read more
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








